Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers

Jose D. Debes, Rosebud O Roberts, Debra J. Jacobson, Cynthia J. Girman, Michael M. Lieber, Donald J. Tindall, Steven J. Jacobsen

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Calcium channel blockers block calcium signal-mediated apoptosis. It is hypothesized that the use of these drugs may be associated with the development of cancer. This study investigated the association between daily use of calcium channel blockers and prostate cancer in a community-based cohort of men who participated in a longitudinal study of lower urinary tract symptoms. Study subjects were men ages 40 to 79 years by January 1, 1990, and were randomly selected from Olmsted County in Minnesota. At baseline, participants underwent an interview to determine all medications taken on a daily basis, including calcium channel blockers and to elicit a family history of prostate cancer. During follow-up, all men with a histological diagnosis of prostate cancer were identified through patient self-report and by a review of the complete medical record. Over 12,668 person years of follow-up, 15 (6.8%) of 220 calcium channel blocker users and 120 (10.5%) of 1142 nonusers developed prostate cancer (P = 0.09; odds ratio, 0.62; 95% confidence interval, 0.36-1.10). With adjustment for age and family history of prostate cancer, the risk (odds ratio, 95% confidence interval) of prostate cancer was 0.55 (0.31-0.97) in calcium channel blocker users compared with nonusers. In analyses stratified by family history of prostate cancer, the risk of prostate cancer was 0.45 (0.23-0.88) in men without a family history and 2.64 (0.82-8.47) in men with a family history of prostate cancer (P = 0.006). These findings suggest an association between prostate cancer and daily use of calcium channel blockers that varies by family history of prostate cancer.

Original languageEnglish (US)
Pages (from-to)255-259
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Calcium Channel Blockers
Prostatic Neoplasms
Odds Ratio
Confidence Intervals
Lower Urinary Tract Symptoms
Self Report
Medical Records
Longitudinal Studies
Interviews
Apoptosis
Calcium

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Debes, J. D., Roberts, R. O., Jacobson, D. J., Girman, C. J., Lieber, M. M., Tindall, D. J., & Jacobsen, S. J. (2004). Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers. Cancer Epidemiology Biomarkers and Prevention, 13(2), 255-259. https://doi.org/10.1158/1055-9965.EPI-03-0093

Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers. / Debes, Jose D.; Roberts, Rosebud O; Jacobson, Debra J.; Girman, Cynthia J.; Lieber, Michael M.; Tindall, Donald J.; Jacobsen, Steven J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 13, No. 2, 02.2004, p. 255-259.

Research output: Contribution to journalArticle

Debes, JD, Roberts, RO, Jacobson, DJ, Girman, CJ, Lieber, MM, Tindall, DJ & Jacobsen, SJ 2004, 'Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers', Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 2, pp. 255-259. https://doi.org/10.1158/1055-9965.EPI-03-0093
Debes, Jose D. ; Roberts, Rosebud O ; Jacobson, Debra J. ; Girman, Cynthia J. ; Lieber, Michael M. ; Tindall, Donald J. ; Jacobsen, Steven J. / Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers. In: Cancer Epidemiology Biomarkers and Prevention. 2004 ; Vol. 13, No. 2. pp. 255-259.
@article{0b62bffe74784c13af2dc3c24e3eb429,
title = "Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers",
abstract = "Calcium channel blockers block calcium signal-mediated apoptosis. It is hypothesized that the use of these drugs may be associated with the development of cancer. This study investigated the association between daily use of calcium channel blockers and prostate cancer in a community-based cohort of men who participated in a longitudinal study of lower urinary tract symptoms. Study subjects were men ages 40 to 79 years by January 1, 1990, and were randomly selected from Olmsted County in Minnesota. At baseline, participants underwent an interview to determine all medications taken on a daily basis, including calcium channel blockers and to elicit a family history of prostate cancer. During follow-up, all men with a histological diagnosis of prostate cancer were identified through patient self-report and by a review of the complete medical record. Over 12,668 person years of follow-up, 15 (6.8{\%}) of 220 calcium channel blocker users and 120 (10.5{\%}) of 1142 nonusers developed prostate cancer (P = 0.09; odds ratio, 0.62; 95{\%} confidence interval, 0.36-1.10). With adjustment for age and family history of prostate cancer, the risk (odds ratio, 95{\%} confidence interval) of prostate cancer was 0.55 (0.31-0.97) in calcium channel blocker users compared with nonusers. In analyses stratified by family history of prostate cancer, the risk of prostate cancer was 0.45 (0.23-0.88) in men without a family history and 2.64 (0.82-8.47) in men with a family history of prostate cancer (P = 0.006). These findings suggest an association between prostate cancer and daily use of calcium channel blockers that varies by family history of prostate cancer.",
author = "Debes, {Jose D.} and Roberts, {Rosebud O} and Jacobson, {Debra J.} and Girman, {Cynthia J.} and Lieber, {Michael M.} and Tindall, {Donald J.} and Jacobsen, {Steven J.}",
year = "2004",
month = "2",
doi = "10.1158/1055-9965.EPI-03-0093",
language = "English (US)",
volume = "13",
pages = "255--259",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Inverse Association between Prostate Cancer and the Use of Calcium Channel Blockers

AU - Debes, Jose D.

AU - Roberts, Rosebud O

AU - Jacobson, Debra J.

AU - Girman, Cynthia J.

AU - Lieber, Michael M.

AU - Tindall, Donald J.

AU - Jacobsen, Steven J.

PY - 2004/2

Y1 - 2004/2

N2 - Calcium channel blockers block calcium signal-mediated apoptosis. It is hypothesized that the use of these drugs may be associated with the development of cancer. This study investigated the association between daily use of calcium channel blockers and prostate cancer in a community-based cohort of men who participated in a longitudinal study of lower urinary tract symptoms. Study subjects were men ages 40 to 79 years by January 1, 1990, and were randomly selected from Olmsted County in Minnesota. At baseline, participants underwent an interview to determine all medications taken on a daily basis, including calcium channel blockers and to elicit a family history of prostate cancer. During follow-up, all men with a histological diagnosis of prostate cancer were identified through patient self-report and by a review of the complete medical record. Over 12,668 person years of follow-up, 15 (6.8%) of 220 calcium channel blocker users and 120 (10.5%) of 1142 nonusers developed prostate cancer (P = 0.09; odds ratio, 0.62; 95% confidence interval, 0.36-1.10). With adjustment for age and family history of prostate cancer, the risk (odds ratio, 95% confidence interval) of prostate cancer was 0.55 (0.31-0.97) in calcium channel blocker users compared with nonusers. In analyses stratified by family history of prostate cancer, the risk of prostate cancer was 0.45 (0.23-0.88) in men without a family history and 2.64 (0.82-8.47) in men with a family history of prostate cancer (P = 0.006). These findings suggest an association between prostate cancer and daily use of calcium channel blockers that varies by family history of prostate cancer.

AB - Calcium channel blockers block calcium signal-mediated apoptosis. It is hypothesized that the use of these drugs may be associated with the development of cancer. This study investigated the association between daily use of calcium channel blockers and prostate cancer in a community-based cohort of men who participated in a longitudinal study of lower urinary tract symptoms. Study subjects were men ages 40 to 79 years by January 1, 1990, and were randomly selected from Olmsted County in Minnesota. At baseline, participants underwent an interview to determine all medications taken on a daily basis, including calcium channel blockers and to elicit a family history of prostate cancer. During follow-up, all men with a histological diagnosis of prostate cancer were identified through patient self-report and by a review of the complete medical record. Over 12,668 person years of follow-up, 15 (6.8%) of 220 calcium channel blocker users and 120 (10.5%) of 1142 nonusers developed prostate cancer (P = 0.09; odds ratio, 0.62; 95% confidence interval, 0.36-1.10). With adjustment for age and family history of prostate cancer, the risk (odds ratio, 95% confidence interval) of prostate cancer was 0.55 (0.31-0.97) in calcium channel blocker users compared with nonusers. In analyses stratified by family history of prostate cancer, the risk of prostate cancer was 0.45 (0.23-0.88) in men without a family history and 2.64 (0.82-8.47) in men with a family history of prostate cancer (P = 0.006). These findings suggest an association between prostate cancer and daily use of calcium channel blockers that varies by family history of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=1242336877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242336877&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-03-0093

DO - 10.1158/1055-9965.EPI-03-0093

M3 - Article

C2 - 14973089

AN - SCOPUS:1242336877

VL - 13

SP - 255

EP - 259

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -